QRL-101 is under clinical development by QurAlis and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication ...

Topiramate is under development for the treatment of obesity, epilepsy and migrane. The drug candidate is administered intravenously, oral and intramuscularly. It is developed using an advanced drug ...

Company Coverage includes Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical, Biocodex, Longboard Pharmaceuticals, Stoke Therapeutics, Thermo Fisher Scientific, Harmony Biosciences Holdings, Ovid ...

Wish granted meaning Breakthrough in Alzheimer's disease imaging diagnosis: FDA approves first tau pathology imaging drug Breakthrough: New vitamin ...

While living with epilepsy can be tough and discomforting with proper care, medications, and lifestyle adjustments one can live a normal life.” What can be done to save the lives of those ...

One large study from Germany showed a hazard ratio of 0.77 (95% CI 0.65-0.90) for epilepsy incidence among ARB users compared with users of other antihypertensive drug classes. An even larger U.S ...

Summary: Out-of-pocket costs for branded drugs for neurological diseases, particularly for multiple sclerosis (MS ... The ...

Shares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had failed a phase 2b trial. The ARISE trial of padsevonil did not reach ...

UK Medical Eligibility Criteria for Contraceptive Use Category 1: A condition for which there is no restriction for the use of the contraceptive method with the condition or in that circumstance.

Patients would pay no more than $25 for certain name-brand medications to treat chronic illnesses, and face no costs for ...